GILD and ACLX Related Headlines
Go Back- Raymond James on Legend Biotech Corp. (LEGN): 'Arcellx Takeout Indicates Legend is Hugely Undervalued'
- Truist Securities Downgrades Arcellx Inc. (ACLX) to Hold
- Gilead to acquire Arcellx for $7.8 billion to gain control of cancer therapy
- Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
- Citi initiates coverage on biotech amid improving sentiment in sector
